Taking On Challenges And Growing? – Avidity Biosciences Inc (RNA)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Avidity Biosciences to Participate in Upcoming Investor Conferences.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Avidity Biosciences Inc is $2.03B. A total of 1.23 million shares were traded on the day, compared to an average of 1.21M shares.

In the most recent transaction, LEVIN ARTHUR A sold 5,000 shares of RNA for 23.97 per share on Mar 19 ’24. After the transaction, the Director now owns 14,830 company shares. In a previous transaction on Mar 13 ’24, MacLean Michael F sold 40,000 shares at 24.52 per share. RNA shares that Chief Financial Officer owns now total 44,093.

Among the insiders who sold shares, Boyce Sarah disposed of 28,000 shares on Mar 12 ’24 at a per-share price of $22.63. This resulted in the President and CEO holding 112,117 shares of RNA after the transaction. In another insider transaction, LEVIN ARTHUR A sold 27,641 shares at $22.03 per share on Mar 12 ’24. Company shares held by the Director now total 14,830.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, RNA has a high of $26.24 and a low of $4.82.

As of this writing, RNA has an earnings estimate of -$0.78 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.67 per share and a lower estimate of -$0.95. The company reported an EPS of -$0.71 in the last quarter, which was 7.80% higher than expectations of -$0.77.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. RNA’s latest balance sheet shows that the firm has $405.54M in Cash & Short Term Investments as of fiscal 2021. There were $11.73M in debt and $29.66M in liabilities at the time. Its Book Value Per Share was $6.32, while its Total Shareholder’s Equity was $381.43M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RNA is Buy with a score of 4.86.

Most Popular

Related Posts